Therapy of Alzheimer's Disease With Neurofeedback
Primary Purpose
Alzheimer Dementia (AD), Elderly
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
rtfMRI neurofeedback training
3T MRI
Sponsored by

About this trial
This is an interventional treatment trial for Alzheimer Dementia (AD) focused on measuring neurofeedback, real-time functional MRI, parahippocampus
Eligibility Criteria
Inclusion Criteria:
- Native speakers of German
- Naive to neurofeedback experiments
- Ability to provide written informed consent
Exclusion Criteria:
- Metallic implants (MR-safety)
- Neurological/psychiatric disease (except Alzheimer's disease in the patient group)
- Use of psychoactive medication (expect medication for Alzheimer's disease)
- Familiarity with the study site
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Sham Comparator
Arm Label
Healthy elderly experimental group
Patient group
Healthy elderly sham-feedback group
Arm Description
Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
Feedback of the postcentral gyrus using rtfMRI neurofeedback training (using 3T MRI).
Outcomes
Primary Outcome Measures
Visual and Verbal Memory Test (VVM)
Neuropsychological assessment including visuo-spatial memory
Secondary Outcome Measures
Montreal Cognitive Assessment (MoCA)
Neuropsychological instrument for a general cognitive screening
Wechsler Memory Scale Revised (WMS-R)
Subtests from the WMS-R were used to assess several domains of memory
Trail Making Test (TMT)
TMT-A and -B were used to assess cognitive processing speed and task switching capabilities.
Visual Patterns Test (VPT)
The VPT was used to assess visual working memory capabilities.
Parahippocampal activation
Activation of the parahippocampal gyrus during neurofeedback training as measured with fMRI
Memory-related functional connectivity using Granger Causality Analysis (GCA)
Change of functional connectivity mainly between memory-associated brain regions over the course of neurofeedback training characterised by GCA
Change of brain structure
Assessment of grey matter volume in the entire brain
Change of brain function
Assessment of activation in the entire brain
Full Information
NCT ID
NCT03070821
First Posted
February 23, 2017
Last Updated
February 28, 2017
Sponsor
University Hospital, Aachen
Collaborators
Alzheimer Forschung Initiative e.V.
1. Study Identification
Unique Protocol Identification Number
NCT03070821
Brief Title
Therapy of Alzheimer's Disease With Neurofeedback
Official Title
Neurofeedback and Follow-up With Real-time fMRI to Investigate Cognitive Function in Patients of Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD)
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
January 30, 2013 (Actual)
Primary Completion Date
June 30, 2016 (Actual)
Study Completion Date
June 30, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital, Aachen
Collaborators
Alzheimer Forschung Initiative e.V.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The project aims to investigate in patients of Alzheimer's disease in a prodromal state (early state of the disease) compared to healthy subjects whether neurofeedback training with functional MRI (fMRI) can improve cognitive ability. It is of interest if voluntary modulation of brain activation with real-time (rt) fMRI as a novel method affects cognitive ability, as well as functional and structural measures of the brain.
Over the course of the study subjects will learn a real-world footpath. During neurofeedback training subjects are then asked to recall this footpath while simultaneously trying to modulate their own brain activation based on feedback. Feedback is given about the parahippocampal gyrus - a region of the brain associated with episodic and visuo-spatial memory, which is known to be affected early by Alzheimer's disease pathology.
Before and after the training cognitive ability is assessed using neuropsychological tests mainly measuring numerous domains of memory.
The investigators hypothesise that the training leads to an improvement of the trained cognitive domain, but also induces changes in brain structure and function.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Dementia (AD), Elderly
Keywords
neurofeedback, real-time functional MRI, parahippocampus
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The design is a pre-test/post-test study with an intervention of three parallel groups. The groups are a healthy elderly experimental group, a patient group and a healthy elderly sham-feedback group.
Masking
Participant
Masking Description
Healthy subjects in the sham feedback condition were not aware of their group membership, but were debriefed at the end of the study.
Allocation
Non-Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Healthy elderly experimental group
Arm Type
Experimental
Arm Description
Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
Arm Title
Patient group
Arm Type
Experimental
Arm Description
Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
Arm Title
Healthy elderly sham-feedback group
Arm Type
Sham Comparator
Arm Description
Feedback of the postcentral gyrus using rtfMRI neurofeedback training (using 3T MRI).
Intervention Type
Other
Intervention Name(s)
rtfMRI neurofeedback training
Intervention Description
Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
Intervention Type
Device
Intervention Name(s)
3T MRI
Intervention Description
A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
Primary Outcome Measure Information:
Title
Visual and Verbal Memory Test (VVM)
Description
Neuropsychological assessment including visuo-spatial memory
Time Frame
2.5 weeks
Secondary Outcome Measure Information:
Title
Montreal Cognitive Assessment (MoCA)
Description
Neuropsychological instrument for a general cognitive screening
Time Frame
2.5 weeks
Title
Wechsler Memory Scale Revised (WMS-R)
Description
Subtests from the WMS-R were used to assess several domains of memory
Time Frame
2.5 weeks
Title
Trail Making Test (TMT)
Description
TMT-A and -B were used to assess cognitive processing speed and task switching capabilities.
Time Frame
2.5 weeks
Title
Visual Patterns Test (VPT)
Description
The VPT was used to assess visual working memory capabilities.
Time Frame
2.5 weeks
Title
Parahippocampal activation
Description
Activation of the parahippocampal gyrus during neurofeedback training as measured with fMRI
Time Frame
2.5 weeks
Title
Memory-related functional connectivity using Granger Causality Analysis (GCA)
Description
Change of functional connectivity mainly between memory-associated brain regions over the course of neurofeedback training characterised by GCA
Time Frame
2.5 weeks
Title
Change of brain structure
Description
Assessment of grey matter volume in the entire brain
Time Frame
2.5 weeks
Title
Change of brain function
Description
Assessment of activation in the entire brain
Time Frame
2.5 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Native speakers of German
Naive to neurofeedback experiments
Ability to provide written informed consent
Exclusion Criteria:
Metallic implants (MR-safety)
Neurological/psychiatric disease (except Alzheimer's disease in the patient group)
Use of psychoactive medication (expect medication for Alzheimer's disease)
Familiarity with the study site
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kathrin Reetz, Prof. Dr.
Organizational Affiliation
University Hospital, Aachen
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Therapy of Alzheimer's Disease With Neurofeedback
We'll reach out to this number within 24 hrs